Eribulin Gets Reviewed, Finally
So it looks like the FDA is giving reviewing Eisai’s oncology drug Eribulin (E7389) a priority review. The company had hoped to get it reviewed three years ago, but the FDA told them to get back into the clinic and collect more data. The compound is being reviewed for advanced breast cancer, and the earlier…